Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amneal Pharmaceuticals Inc (NY: AMRX ) N/A UNCHANGED Last Price Updated: 7:00 PM EST, Dec 26, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Amneal Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 Next > Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California May 22, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal to Participate at Upcoming Investor Conference May 22, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade May 16, 2024 The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. Via InvestorPlace Topics Intellectual Property Exposures Intellectual Property Assessing Amneal Pharmaceuticals: Insights From 4 Financial Analysts May 06, 2024 Via Benzinga Generic Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit Settlement May 03, 2024 Amneal Pharmaceuticals settles $270 million opioid crisis agreement, offering cash and naloxone spray. Boosted by strong Q1 earnings, the company reaffirms fiscal guidance. Via Benzinga Topics Lawsuit Exposures Financial Legal Amneal Pharmaceuticals: Q4 Earnings Insights March 01, 2024 Via Benzinga Earnings Outlook For Amneal Pharmaceuticals February 29, 2024 Via Benzinga AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 May 03, 2024 AMRX stock results show that Amneal Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Amneal Reports First Quarter 2024 Financial Results May 03, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose April 24, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine April 16, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal to Report First Quarter 2024 Results on May 3, 2024 April 10, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 March 28, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension March 25, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Why Is Generic Drug-Focused Amneal Pharmaceuticals Stock Trading Lower Friday? March 01, 2024 Amneal Pharmaceuticals reveals Q4 2023 results with $616.98 million revenue, up 1% YoY. Despite an 8% drop in adjusted EBITDA, the company beats EPS expectations. Co-CEOs anticipate growth in 2024,... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday March 01, 2024 Pre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news! Via InvestorPlace Earnings Scheduled For March 1, 2024 March 01, 2024 Companies Reporting Before The Bell • McEwen Mining (NYSE:MUX) is estimated to report quarterly loss at $0.28 per share on revenue of $71.72 million. Via Benzinga Amneal Reports Fourth Quarter and Full Year 2023 Financial Results March 01, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203 February 27, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire 6 reasons to buy Teva Pharmaceuticals stock sooner than later February 26, 2024 Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why Via MarketBeat Topics Lawsuit Exposures Financial Legal Amneal to Participate at Upcoming Investor Conference February 13, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024 January 31, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension January 10, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023 January 04, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference December 21, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Announces Move to Nasdaq December 15, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone) December 07, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules December 01, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Reports Third Quarter 2023 Financial Results November 07, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal to Participate at Upcoming Investor Conferences November 03, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.